SCHEMBL6016494

SCHEMBL6016494

CC(C)[C@H](CO)Nc1nc(N[C@@H](CO)c2ccccc2)c2ncn(C(C)C)c2n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 14/20 0.72
CDK1 P06493 7/20 0.72
CDK2 P24941 13/20 0.68
CCNA2 P20248 12/20 0.68
CCNA1 P78396 12/20 0.68
DYRK1A Q13627 12/20 0.68
CDK5R1 Q15078 12/20 0.68
CCNB2 O95067 3/20 0.66
CCNB1 P14635 3/20 0.66
CCNB3 Q8WWL7 3/20 0.66
CCNE1 P24864 2/20 0.62
KDM4E B2RXH2 1/20 0.62
MEN1 O00255 1/20 0.62
PAK4 O96013 1/20 0.62
CCNE2 O96020 1/20 0.62
ALDH1A1 P00352 1/20 0.62
TP53 P04637 1/20 0.62
CYP1A2 P05177 1/20 0.62
INSR P06213 1/20 0.62
CYP3A4 P08684 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6016491 1.00 CDK5 (0.72) CDK5CDK1CDK2CCNA2CCNA1
SCHEMBL6016653 1.00 CDK5 (0.72) CDK5CDK1CDK2CCNA2CCNA1
SCHEMBL6016657 1.00 CDK5 (0.72) CDK5CDK1CDK2CCNA2CCNA1
SCHEMBL6016726 1.00 CDK5 (0.72) CDK5CDK1CDK2CCNA2CCNA1
SCHEMBL6016536 0.86 CDK1 (0.72) CDK5CDK1CDK2CCNA2CCNA1
SCHEMBL6016531 0.86 CDK1 (0.72) CDK5CDK1CDK2CCNA2CCNA1
SCHEMBL6016588 0.85 CDK1 (0.71) CDK5CDK1CDK2CCNA2CCNA1
SCHEMBL6016542 0.85 CDK1 (0.71) CDK5CDK1CDK2CCNA2CCNA1
SCHEMBL6016540 0.85 CDK1 (0.71) CDK5CDK1CDK2CCNA2CCNA1
SCHEMBL1218376 0.84 CDK1 (1.00) CDK5CDK1CDK2CCNA2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244668-B1 PURINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE THEREOF UNIVERSITAIRE INSTELLING ANTWE (BE) 2006-04-05 EP claimed
US-20030187261-A1 Purine derivatives, process for their preparation and use thereof USTAV EXPERIMANTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) 2003-10-02 US claimed
EP-1244668-A1 PURINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE THEREOF UNIVERSITAIRE INSTELLING ANTWERPEN (BE) 2002-10-02 EP claimed
WO-2001049688-A1 PURINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE THEREOF UNIVERSITAIRE INSTELLING ANTWERPEN (BE) 2001-07-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187261-A1 Purine derivatives, process for their preparation and use thereof DCK, DTYMK, CCNK CDK5 23/4885CDK1 7/4885CDK2 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.